At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 120 enrolled
Drug / intervention
Desoximetasone Spray 0.25% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Vehicle-Controlled, Randomized, Parallel Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone 0.25% Topical Spray in Patients With Moderate to Severe Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating Desoximetasone Spray 0.25% and placebo for Psoriasis. Completed, enrolled 120 participants across 1 site.
Detailed Summary
The objective of this study is to demonstrate that desoximetasone 0.25% topical spray is effective for the treatment of patients with moderate to severe plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2010
First PostedSep 2010
Primary CompletionDec 2010
Study CompletionJan 2011
TodayJul 2026
First PostedSep 22, 2010
Enrollment StartAug 1, 2010
Primary CompletionDec 1, 2010
Study CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 15.8 years ago
Interventions
Desoximetasone Spray 0.25%drug
Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
placebodrug
Placebo administered to affected area twice a day for 28 days